Evidence map›Paper›PMID 36408899›Full record

ArticleCNS oncology2022

Undesired impact of iron supplement on MRI assessment of post-treatment glioblastoma.

Dahye Park, Mina Lobbous, Louis B Nabors, James M Markert, Jinsuh Kim

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Dahye ParkSchool of Medicine, University of Alabama at Birmingham, AL 35233, USA.ORCID 0000-0002-4305-0388
Mina LobbousDepartment of Neurology, Division of Neuro-oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
Louis B NaborsDepartment of Neurology, Division of Neuro-oncology, University of Alabama at Birmingham, AL 35233, USA.
James M MarkertDepartment of Neurosurgery, University of Alabama at Birmingham, AL 35233, USA.
Jinsuh KimDepartment of Radiology & Imaging Sciences, Division of Neuroradiology, Emory University, GA 30322, USA.
University of Alabama at Birmingham · USCleveland Clinic · USEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common malignant adult brain and has a poor prognosis. Routine post-treatment MRI evaluations are required to assess treatment response and disease progression. We present a case of an 83-year-old female who underwent MRI assessment of post-treatment GBM after intravenous iron replacement therapy, ferumoxytol. The brain MRI revealed unintended alteration of MRI signal characteristics from the iron containing agent which confounded diagnostic interpretation and subsequently, the treatment planning. Ferumoxytol injection prior to contrast enhanced MRI must be screened in post-treatment GBM patients to accurately evaluate tumor activity.

Indexed as

Brain NeoplasmsGlioblastomaAdultAged, 80 and overContrast MediaFemaleFerrosoferric OxideHumansIronMagnetic Resonance ImagingContrast MediaFerrosoferric OxideIronadverse eventsbrain tumorferumoxytolGBMimaging

Identifiers

PMID36408899
PMCPMC9830595
OpenAlexW4309508581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.